See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Intuitive Surgical, Inc. (ISRG) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical, Inc. (ISRG) - free report >>
Image: Bigstock
Intuitive Surgical: Forex & Regulatory Woes Continue to Hurt
On Jun 21, we issued an updated research report on Sunnyvale based Intuitive Surgical (ISRG - Free Report) – manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories. The company currently carries a Zacks Rank #4 (Sell).
Over the last 60 days, the Zacks Consensus Estimate for full-year 2016 earnings moved down by 11 cents to $17.56 per share, as most analysts revised their estimates downward.
In the past, the company faced several headwinds including delayed market acceptance of new products (risk of procedure adoption). Other than that, unfavorable currency fluctuation impacted the company’s growth trajectory to a large extent, as the company is expanding its presence in international markets. Increasing regulatory headwinds and low capital investment in hospitals are the other dampeners.
On the positive side, Intuitive Surgical reported impressive first-quarter 2016 results with both earnings and revenues steering past the Zacks Consensus Estimate. Expenses on research and development (R&D) increased significantly in the first quarter, reflecting high spending on advanced imaging, advanced instrumentation and next-generation robotics.
In the long haul, extensive expenditure on product pipeline and expansion in international markets like Europe should drive growth for the company.
Stocks to Consider
Better-ranked stocks in the same space include Cryolife Inc , IRadimed Corp (IRMD - Free Report) and Masimo Corporation (MASI - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>